STAAR SURGICAL CO
STAAR Surgical designs, develops, manufactures and sells implantable lenses and delivery systems for ophthalmic surgery. It makes most of its sales from Implantable Collamer Lenses, or ICLs, used in refractive surgery to correct vision. Its products include the EVO family, including EVO ICL, EVO+ ICL, EVO Visian ICL and EVO Viva, as well as Visian ICL for farsightedness. The foldable lenses are implanted while the eye’s natural lens remains in place and are available in multiple models and prescription powers. STAAR sells to ophthalmic surgeons and other healthcare providers through its own sales representatives and independent distributors. Its corporate headquarters and executive offices are in Lake Forest, California. The company also has manufacturing, administrative and distribution facilities in the United States, Switzerland and Japan.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $STAA in the last 7 days.
No SEC Form 4 filings for $STAA in the last 30 days.
See all $STAA insider activity →STAAR Surgical reported Q3 2026 revenue of $83.41M, beating estimates by 6.7%. EPS of $0.11 exceeded forecasts, and adjusted EBITDA was $14.36M, a 19.5% beat. Operating margin declined to 6.5%, while free cash flow margin rose to 31.6%.
STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA [1] of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Q
SoftBank Group is in early talks to acquire Allied Universal for $30B ($18B equity, $12B debt). Allied, with $22.6B revenue, is a security firm with 800,000 employees. SoftBank's interest aligns with its AI and robotics ambitions, according to Reuters. Allied's CEO Steve Jones has focused on tech advances, including robotics. SoftBank's local investments include Sprint Corp. and Kingston Technology, with mixed outcomes.
Recent STAA coverage spans earnings, financial news and mergers & acquisitions.
Earnings beat and strong cash flow suggest upside pressure.
Earnings miss on revenue may weigh on the stock, but the new buyback could provide support.
Rejection leaves Staar independent; share price remains pressured after failed deal.
Earnings release timing announced; no new financial data disclosed.
The earnings beat was strong, yet the share price fell, indicating market concerns over valuation or guidance.
AlphAI scores every news story that mentions STAA with an AI model for sentiment and relevance, and aggregates insider trades from STAAR SURGICAL CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
STAAR Surgical reported Q3 2026 revenue of $83.41M, beating estimates by 6.7%. EPS of $0.11 exceeded forecasts, and adjusted EBITDA was $14.36M, a 19.5% beat. Operating margin declined to 6.5%, while free cash flow margin rose to 31.6%.
STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA [1] of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Q
SoftBank Group is in early talks to acquire Allied Universal for $30B ($18B equity, $12B debt). Allied, with $22.6B revenue, is a security firm with 800,000 employees. SoftBank's interest aligns with its AI and robotics ambitions, according to Reuters. Allied's CEO Steve Jones has focused on tech advances, including robotics. SoftBank's local investments include Sprint Corp. and Kingston Technology, with mixed outcomes.
STAAR Surgical (NASDAQ: STAA) will release its third-quarter 2026 financial results after markets close on Nov. 4. A webcast is scheduled for 5:30 p.m. ET, with a replay available for 90 days. Investors can submit questions in advance. STAAR is a global leader in implantable phakic intraocular lenses, with over 4 million ICLs sold in 85 countries.
STAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
Analysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
Staar Surgical (STAA) shares rose nearly 8% after Stifel's Thomas Stephan upgraded the stock to buy from hold, raising the price target to $31. He cited positive sales momentum, particularly in China, and potential for acquisitions. The company's FDA-approved products and lean operations were also highlighted.
Wall Street analyst research calls on Tuesday included upgrades for Kroger (KR), Netflix (NFLX), and others, while PepsiCo (PEP), Ryder Systems (R), and more were downgraded. Futures traded higher after a rough start to the week, with major indices closing lower. Treasury yields rose, oil prices surged, and gold and crypto markets declined.
Analysts updated price targets for several companies. Baird cut Boot Barn (BOOT) to $160, Stifel lowered Vail Resorts (MTN) to $157, Mizuho cut Stitch Fix (SFIX) to $2.5, BTIG boosted Robinhood (HOOD) to $135, Cantor Fitzgerald cut Western Union (WU) to $6, Deutsche Bank cut Netflix (NFLX) to $95, BNP Paribas cut Rollins (ROL) to $35, Stifel raised STAAR Surgical (STAA) to $31, B of A Securities cut Bending Spoons (BSP) to $36, BMO Capital raised American Eagle (AEO) to $20.
Stifel upgraded STAAR Surgical (STAA) to Buy, raising its price target to $31. The firm expects China-driven growth and improved market conditions to boost sales. STAA reported Q2 2026 revenue of $93.5M, beating estimates, but EPS missed. The stock trades at $20.87, below a Fair Value estimate of $26.45. Analysts have mixed outlooks, with targets ranging from $28 to $33.
